Jerusalem [Israel], December 22 (ANI/TPS): Netanya-based biotechnology startup BioGenCell announced it has received the US Food and Drug Administrations Fast Track Designation for BGC101, a personalized cell therapy for severe Critical Limb Threatening Ischemia (CLTI).